Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

644
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
644
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

281
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
281
Bacterial Signaling01:30

Bacterial Signaling

43.0K
Bacterial signaling can occur within bacteria (intracellular) or between bacteria (intercellular). At times, a group of bacteria behaves like a community. To achieve this, they engage in quorum sensing, the perception of higher cell density that causes changes in gene expression. Quorum sensing involves both extracellular and intracellular signaling. The signaling cascade starts with a molecule called an autoinducer (AI). Individual bacteria produce AIs that move out of the bacterial cell...
43.0K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

64
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can universal cervical length screening with vaginal progesterone for a short cervix reduce preterm birth? A systematic review and meta-analyses.

Acta obstetricia et gynecologica Scandinavica·2026
Same author

Parenteral clomipramine for depression or obsessive-compulsive disorder: a systematic review and meta-analysis.

Acta neuropsychiatrica·2026
Same author

Corrigendum: Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.

Frontiers in medicine·2025
Same author

Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.

Frontiers in medicine·2023
Same author

Response to professor Milgrom.

Gerodontology·2023
Same author

Safety, effectiveness, women's experience, and economic costs of outpatient induction in women with uncomplicated pregnancies: A systematic review and meta-analyses.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2022

Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K

[Better regulatory framework needed for medical devices].

Henrik Sjövall1, Petteri Sjögren2

  • 1Institute of Medicine - Göteborg, Sweden Institute of Medicine - Göteborg, Sweden.

Lakartidningen
|March 9, 2016
PubMed
Summary

Drug-eluting stents and balloons show low certainty evidence for reducing restenosis in lower extremity arterial disease. However, a concerning safety signal indicates an increased risk of amputation in specific patient groups.

More Related Videos

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding
10:43

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding

Published on: June 27, 2014

20.6K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

672

Related Experiment Videos

Last Updated: Mar 24, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K
Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding
10:43

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding

Published on: June 27, 2014

20.6K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

672

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Health Technology Assessment

Background:

  • Atherosclerotic disease in the lower extremities is a significant health concern.
  • Drug-eluting stents and balloons are utilized for treating peripheral arterial disease.
  • Patient values and evidence for these devices require thorough evaluation.

Purpose of the Study:

  • To summarize a Health Technology Assessment (HTA) report on patient values regarding drug-eluting stents and balloons.
  • To evaluate the efficacy and safety of these devices for atherosclerotic disease in lower extremities.
  • To assess the certainty of evidence for clinical outcomes.

Main Methods:

  • Systematic review of 17 randomized controlled trials, 4 cohort studies, and 13 case series.
  • Analysis of approximately 3,000 patients with lower extremity atherosclerotic disease.
  • GRADE methodology used to assess the certainty of evidence.

Main Results:

  • Low certainty of evidence (GRADE ++) for reduced restenosis risk in critical ischemia, below-knee lesions.
  • Modest beneficial effect on ischemic symptoms in a mixed patient population.
  • Identified a worrying safety signal: increased risk of amputation in patients with below-knee critical ischemia.

Conclusions:

  • Evidence for drug-eluting devices in lower extremity arterial disease is limited by heterogeneity.
  • A significant safety concern regarding amputation risk necessitates careful consideration.
  • Highlights the need for a structured medical device validation system, similar to pharmaceuticals.